|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
The S wedish WntResearch drug candidate Foxy-5 has emerged as a possible new blockbuster in a novel cancer treatment concept targeting the lethal metastatic process by agonising the Wnt-5a signaling pathway in breast, colon and prostate cancer. infoom.se
The Phase Ib study is finished positive resultshttps://www.aktietorget.se/NewsItem.aspx?ID=82730 allthough the final results are not complete yet.
They are obviously (even the CSO confimed this last spring) in talks with Big Pharma regarding Foxy-5, and surprisingly Aug 17 in the Q2 report declared they took a small loan SEK 10 million instead of a bigger ne w stock emission to current stock holders for financing of the Phase II study scheduled to begin this year. It seems that they want to gain time and put pressure on Big Pharma, possibly more than one BP...
The market has deduced that there might be a deal with Big Pharma instead and relatively soon and the stock has rallied : finance.yahoo.com
A deal COULD be worth several times the current stock price.
ATH is still far away though at SEK 79 from November 2015. The absolute risk is high but risk/re ward very very good in my vie w.
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|